European Multicentre Association Study of Schizophrenia: A study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 81, Issue 1, 1998, Pages 24-28

  Spurlock, G ^a   Williams, J ^a   McGuffin, P ^a   Aschauer, H N ^b   Lenzinger, E ^b   Fuchs, K ^b   Sieghart, W C ^b   Meszaros, K ^b   Fathi, N ^b   Laurent, C ^c   Mallet, J ^c   Macciardi, F ^d   Pedrini, S ^c   Gill, M ^e   Hawi, Z ^e   Gibson, S ^e   Jazin, E E ^f   Yang, Hai Tao ^f   Adolfsson, R ^g   Pato, C N ^h,i   Dourado, A M ^j   Owen, M J ^a   more..

^a CARDIFF UNIVERSITY   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF MILAN   (Italy)

^e ST JAMES S HOSPITAL   (Ireland)

^f Biomedical Centre   (Sweden)

^g UMEÅ UNIVERSITY   (Sweden)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ UNIVERSITY OF COIMBRA   (Portugal)

^j UNIVERSITY OF COIMBRA   (Portugal)

more..

Author keywords

Association; Dopamine DRD2; Dopamine DRD3; Schizophrenia

Indexed keywords

CYSTEINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GLYCINE; SERINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA;

ALLELES; CYSTINE; GENE FREQUENCY; GENOTYPE; GLYCINE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SERINE;

GENETTA;

EID: 0032492163     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19980207)81:1<24::AID-AJMG5>3.0.CO;2-N     Document Type: Article

References (6)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westpahl H, Fuchs S (1996): A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Nat Acad Sci 93:1945-1949.
2. Arinami T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H, Hamaguchi H, Toru M (1994): Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 343:703-704.
3. Arinami T, Itokawa M, Aoki J, Shibuya H, Ookubo Y, Iwawaki A, Ota K, Shimizu H, Hamaguchi H, Toru M (1996): Further association study on dopamine D2 receptor variant Ser311Cys in schizophrenia and affective-disorders. Am J Med Genet 67:133-138.
4. Asherson P, Williams N, Roberts E, McGuffin M, Owen M (1994): DRD2 Ser311/Cys311 polymorphism in schizophrenia (Letter). Lancet 343:1044-1045.
5. Carlsson A (1988): The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186.
6. Chen CH, Chien SH, Hwu HG (1996): No association of dopamine D2 receptor molecular variant Cys311 and schizophrenia in Chinese patients. Am J Med Genet 67:418-420.